Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial - The Lancet - 2003
Brief Summary:
Among patients LVEF ≤40% and NYHA class II-IV symptoms on an ACE-inhibitor, the addition of candesartan reduced CV mortality or HF hospitalization when compared to placebo.Reference: http://www.ncbi.nlm.nih.gov/pubmed/13678869
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you